MedTrace Logo

Safety and Immune Response of COVID-19 Vaccination in Patients With Basic Disease

NCT05043246 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 2300

Last updated 2022-08-10

No results posted yet for this study

Summary

On 11 February 2020, the International Committee for the Classification of Viruses named the disease caused by SAＲS-CoV-2 infection in humans as the new coronavirus pneumonia (coronavirus disease 2019, COVID-19).Due to the decline of immunity and cardiopulmonary function in patients with basic diseases (hypertension, diabetes, chronic obstructive pulmonary disease, chronic kidney disease, cancer diseases, etc.), COVID-19 's severe illness and mortality mainly increase in these special population. Vaccination of COVID-19 vaccine can effectively prevent COVID-19 virus infection and delay or prevent patients from developing into critical illness and reduce mortality.To evaluate the safety and effectiveness of the population vaccinated with COVID-19 vaccine, and to play a scientific and theoretical supporting role in guiding COVID-19 vaccination scientifically, reasonably and effectively, so this study was carried out.

Conditions

  • Diseases, Chronic
  • Covid19
  • Adverse Reaction to Vaccine

Interventions

BIOLOGICAL

SARS-COV-2 VACCINE

the antibody titer and adverse reactions were observed.

Sponsors & Collaborators

  • The Second Affiliated Hospital of Chongqing Medical University

    lead OTHER

Principal Investigators

  • Hong Ren, PH D · The Second Affiliated Hospital of Chongqing Medical University

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-08-01
Primary Completion
2023-05-01
Completion
2023-08-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05043246 on ClinicalTrials.gov